Zydus Reports Positive Phase 2/3 Results for Saroglitazar Trial
August 29, 2025
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3